KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Sarepta Therapeutics (SRPT) over the last 10 years, with Q3 2025 value amounting to $83.0 million.

  • Sarepta Therapeutics' Change in Inventory rose 1769.38% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $481.2 million, marking a year-over-year increase of 4688.8%. This contributed to the annual value of $395.2 million for FY2024, which is 16752.37% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Change in Inventory is $83.0 million, which was up 1769.38% from $59.2 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Change in Inventory peaked at $177.4 million during Q1 2025, and registered a low of $306000.0 during Q1 2023.
  • For the 5-year period, Sarepta Therapeutics' Change in Inventory averaged around $52.5 million, with its median value being $27.3 million (2021).
  • Its Change in Inventory has fluctuated over the past 5 years, first tumbled by 9347.13% in 2023, then soared by 1967516.34% in 2024.
  • Sarepta Therapeutics' Change in Inventory (Quarter) stood at $27.3 million in 2021, then plummeted by 67.43% to $8.9 million in 2022, then surged by 959.73% to $94.1 million in 2023, then surged by 71.79% to $161.7 million in 2024, then plummeted by 48.64% to $83.0 million in 2025.
  • Its last three reported values are $83.0 million in Q3 2025, $59.2 million for Q2 2025, and $177.4 million during Q1 2025.